Phase II Study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Itacitinib (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Jun 2018 Status changed from not yet recruiting to recruiting.
- 04 Jun 2018 Planned End Date changed from 1 Mar 2021 to 1 Jun 2021.